Professional research reports powered by Noah AI — grounded in 100M+ sources including PubMed, clinical trials, guidelines, and patents.
EV plus pembrolizumab is the optimal first-line regimen for most advanced urothelial carcinoma patients, with platinum chemotherapy reserved for specific high-risk cases.
Biomarkers guide precise targeted therapy and safety management for urothelial bladder cancer.
Biomarkers guide precise targeted therapy and safety management for urothelial bladder cancer.
Nivo+ipi beats chemo for unresectable MPM, especially non-epithelioid.
MM care evolves with CAR-T, bispecifics, and MRD-driven strategies.
Systemic flaws hinder standardized bladder cancer treatment across China.
Biomarkers serve multi-layered roles in mesothelioma diagnosis, prognosis and targeted therapy.
Dara-Rd vs VRd: efficacy, safety, and QoL differ in TIE NDMM.
Global mesothelioma care faces four key unmet needs.
MM care converges in US/China, with access gaps shaping real-world practice.
MM shows rising global burden with obvious regional, demographic disparities and varied risk factors
Precision oncology has advanced across major cancers, yet inequitable biomarker testing, reimbursement, and infrastructure constrain real-world therapeutic access.
Global cancer burden is rising, with marked regional disparities driven by screening access, treatment capacity, socioeconomic development, and modifiable risk exposures.
Obesity and T2DM promote endometrial carcinogenesis via metabolic-endocrine dysregulation; metformin shows mechanistic promise but lacks definitive preventive evidence.
Cushing’s syndrome diagnosis requires stepwise biochemical confirmation, etiologic localization, and treatment-directed classification to prevent misdiagnosis and optimize outcomes.
ACC prognosis relies on ENSAT stage, resection status, Ki-67, histopathology, and molecular heterogeneity; predictive mitotane biomarkers remain unvalidated.
AI-assisted dermoscopy shows dermatologist-level sensitivity for melanoma detection, but requires broader prospective validation across diverse populations and clinical workflows.
Evidence supports immunotherapy-first sequencing for BRAF V600E-mutant advanced melanoma, reserving BRAF/MEK inhibitors for urgent cytoreduction.
Alcohol increases site-specific cancer risk through dose-dependent carcinogenic mechanisms, with no safe threshold best supported for breast and esophageal cancers.
Alcohol promotes dose-dependent carcinogenesis through acetaldehyde genotoxicity, oxidative stress, and epigenetic dysregulation, supporting prevention-focused clinical and policy interventions.